Spirulina and cardiovascular disease.

ASCVD and endothelial oxidative stress

• Endothelial dysfunction: The initiating lesion in atherosclerosis is endothelial dysfunction: loss of basal endothelial nitric oxide synthase (eNOS) activity, reduced NO bioavailability, and increased endothelial permeability to apoB-containing lipoproteins (LDL, lipoprotein(a)). Oxidative stress reduces eNOS cofactor availability (BH4, tetrahydrofolate), causing eNOS uncoupling: instead of producing protective NO, the enzyme produces superoxide. Spirulina enhances eNOS expression and stabilises BH4, restoring eNOS coupling and NO bioavailability.
• Monocyte NOX2 and foam cell formation: LDL trapped in the arterial intima is oxidatively modified by endothelial and monocyte NOX2, producing lipid peroxides (oxidised phospholipids, oxidised cholesterol esters). Oxidised LDL (oxLDL) is taken up by monocytes and macrophages via scavenger receptors (SR-A, LOX-1), driving foam cell formation. Foam cells produce IL-6, TNF-α, and matrix metalloproteinases, amplifying atherosclerotic plaque inflammation. Phycocyanobilin NOX2 inhibition reduces monocyte ROS production and foam cell activation.
• Lipid peroxidation and NF-κB: Oxidised LDL and its lipid peroxide components activate macrophage NF-κB via toll-like receptors (TLR4, TLR6), triggering IL-6 and TNF-α production. Phycocyanobilin inhibits NF-κB directly, suppressing this amplification loop. This is the same pathway relevant to rheumatoid arthritis and ankylosing spondylitis.
• NK stimulation concern: ASCVD is atherosclerotic macrophage-driven inflammation, not NK cell-mediated. NK stimulation concern is low in stable ASCVD or post-MI patients on no immunosuppressive therapy. Post-ACS (acute coronary syndrome) on dual antiplatelet therapy (aspirin + clopidogrel): no NK concern specific to antiplatelet mechanisms. Rare post-MI immunosuppression (fulminant myocarditis, high-dose corticosteroids) raises NK concern moderately; discuss with cardiologist.

Drug interactions

Statins (atorvastatin, rosuvastatin, pravastatin)

• Statins are first-line lipid-lowering therapy in stable ASCVD and post-ACS. Most statins (atorvastatin, simvastatin, lovastatin) are CYP3A4-metabolised. Rosuvastatin, pravastatin are not CYP-metabolised. Spirulina does not inhibit CYP3A4 at physiological doses. No pharmacokinetic interaction documented. Time-separation practical: statins taken in evening; spirulina in morning or with lunch. Spirulina NOX2 inhibition complements statin pleiotropic anti-inflammatory effects (both reduce macrophage IL-6/TNF-α). Safe to co-use.

ACE inhibitors and ARBs

• ACE inhibitors (lisinopril, enalapril) and ARBs (losartan, candesartan) are standard post-ACS therapy. No pharmacokinetic interaction with spirulina. Spirulina endothelial NO enhancement may modestly complement ACE inhibitor/ARB vasodilation and remodelling prevention.

Beta-blockers

• Beta-blockers (metoprolol, carvedilol) reduce post-ACS mortality via heart rate and contractility reduction. No interaction with spirulina. Carvedilol has additional alpha-blocking and antioxidant effects; spirulina NOX2 inhibition is complementary.

Dual antiplatelet therapy (DAPT): Aspirin and clopidogrel (Plavix)

• DAPT is standard post-ACS for 12 months (aspirin indefinitely). Aspirin and clopidogrel are antiplatelet agents (inhibit platelet aggregation), not immunosuppressive. Spirulina has mild antiplatelet effects (via omega-3 ALA ~6–7% dry weight and eicosapentaenoic acid traces), but at 3–5 g/day, this is negligible in DAPT context. No pharmacokinetic interaction. If bleeding concern arises (unusual), can time-separate spirulina and clopidogrel administration by 2 hr.

ACE inhibitors/ARBs + Aldosterone antagonists (spironolactone)

• Post-MI with reduced ejection fraction (HFrEF): triple blockade (ACE-I, beta-blocker, aldosterone antagonist) is standard. Spironolactone potassium-sparing effects: spirulina is ~1–2 mEq potassium/5 g (negligible at standard doses). No interaction; monitor potassium in HFrEF on triple blockade as part of routine care.

Anticoagulation (warfarin, DOACs)

• Warfarin: spirulina contains vitamin K (~20–30 µg/10 g), which antagonises warfarin. Consistent daily spirulina dosing is essential; INR check 2 weeks after starting. DOACs (apixaban, rivaroxaban, dabigatran): no vitamin K sensitivity; no interaction. Atrial fibrillation post-ACS on DOAC is safe with spirulina.

Practical guidance

• Stable ASCVD on statin + ACE-I/ARB + beta-blocker: low NK concern; 3–5 g/day spirulina appropriate; separates statin dosing (evening statin, morning spirulina practical)
• Post-ACS on DAPT + ACE-I + beta-blocker: low NK concern; 3–5 g/day appropriate; supports cardiac rehabilitation and anti-inflammatory recovery
• HFrEF on triple blockade (ACE-I, beta-blocker, spironolactone): routine potassium monitoring sufficient; spirulina dosing ~3–5 g/day; no specific NK or potassium concern at this dose
• Atrial fibrillation post-ACS on DOAC: no warfarin vitamin K interaction; spirulina 3–5 g/day safe
• Warfarin-anticoagulated ASCVD: consistent daily spirulina dosing; INR check 2 weeks after starting; maintain stable daily amount thereafter
• Spirulina complements cardiac rehabilitation: endothelial NO support, anti-inflammatory NOX2 inhibition, and complete protein for exercise recovery